GSE124622
Next Generation Sequencing of control (Untreated), PAN injured and Adriamycin injured human podocytes
Purpose: Next-generation sequencing (NGS) was used to identify cellular pathways and genes through systems-based analysis. The goals of this study are to identify NGS-derived transcriptome profiling (RNA-seq) in control (untreated) and Injured (PAN and Adriamycin) podocyte. These high throughput data were further validated through qRT–PCR methods to confirm the cellular pathways and genes affected due to the podocyte injury. Methods: Human podocytes were differentiated for 14 days by thermoswitching from 33°C to 37°C and removal of growth factors, insulin-transferrin-selenium from the medium.  These podocytes were incubated 4hour in serum free RPMI medium and injury was induced by using PAN (100µg/ml) and Adriamycin (0.25µg/ml) treatment for 48 hours.Further, podocytes were processed for RNA isolation and submitted to Medical University of South Carolina Sequencing Core facility for RNA-Seq. All the experiments were performed in triplicates. Conclusions: Our study is first to describe the detailed analysis of PAN and Adriamycin induced podocyte transcriptomes using the RNA-seq technology. A comparative analysis of the differential expression profile was obtained between control vs PAN injured podocytes, and control vs Adriamycin injured podocytes. Complex genetic network and genes effected due to the injury will provide a platform to define biological pathways participate during podocytes injury process. Overall design: Human podocytes mRNA profiles in control (untreated) and PAN/Adriamycin injured podocytes were generated by deep sequencing, in triplicate, using Illumina. contributor: MUSC Sequencing Core Facility